Lilly Prepares For Zyprexa Expiration; Increases R&D Spend
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly's earnings are in line with analyst expectations, but higher costs cut into profits as the company prepares for a revenue decline.
You may also be interested in...
Lilly Disappoints Street, But Stays Its Course
Eli Lilly & Co. failed to meet the Street’s expectations on Jan. 5 when it held a guidance call with analysts, largely due to the rapid erosion of its newly genericized antipsychotic Zyprexa.
Zyprexa Goes Generic: Teva Fills "Basket" Of Doses With Dr. Reddy's Deal
Teva Pharmaceutical Industries greeted the patent expiration of Lilly’s Zyprexa (olanzapine) by launching all six tablet doses of the antipsychotic, thanks to an agreement with Dr. Reddy’s Laboratories Ltd.
Xigris Withdrawal’s Impact On Lilly Is Minimal, But Leaves BioCritica Pondering Its Future
Key business questions linger following Eli Lilly & Co.’s announcement on Oct. 25 that it is withdrawing its troubled sepsis drug Xigris from all markets: What’s the impact of the action on Lilly, and what’s next for BioCritica Inc., the start-up formed largely to take over the drug’s commercialization?